BCAX Bicara Therapeutics Inc.

NASDAQ
$19.21

Bicara Therapeutics Inc. (BCAX) is expected to report earnings on November 10, 2026, before the market open. The consensus earnings estimate is a loss of $0.84 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -15.8% since its last earnings release on August 11, 2026.

Bicara Therapeutics Inc. Missed Consensus Estimates
Tuesday, August 11, 2026 · 7:30 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 10
Tuesday · 7:30 AM ET
Earnings Whisper
-
vs ($0.84)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $23.46

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Bicara Therapeutics Inc.

Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.